About Roche & The Lung Division
Since 1969, Roche has supplied over 100 medicines to New Zealand with a focus on cancer therapies. In their lung division, Roche supplies Alecensa, Avastin, Tarceva, and TECENTRIQ to New Zealanders. TECENTRIQ is the latest medicine to join the lung division treating the most common lung cancer, metastatic Non-Small Cell Lung Cancer. Its rival, Keytruda, was released earlier and has been labelled a wonder drug by the media, but Keytruda can only be used in about 50% of patients and TECENTRIQ can be used in 100% of patients. Preliminary trials show TECENTRIQ may be a more effective treatment option than Keytruda and studies show clearly that TECENTRIQ is a more effective treatment option than chemotherapy.
About My Work
Along with several agencies, I was asked to deliver a positioning proposal for TECENTRIQ that would place it as the first choice for Health Care Providers looking to treat mNSCLC. I developed TECENTRIQ’s positioning with Product Strategist Simon Couldstone.
This was accepted by Roche and is being rolled out currently.
I have produced the following for Roche:
Interactive PDF / Word Forms
For use when ordering TECENTRIQ
Informational documents for digital / print
Leave Pieces & Booklets
For patients, HCPs, and stakeholders
Custom EDM Templates
For TECENTRIQ, Alecensa & Avastin
TECENTRIQ & Roche Brands Pull-Up Banners
Branded Pens & Post-It Notes
Marketing collateral for TECENTRIQ
Interactive Digital Sales Aid (DSA)
Interactive PDF Sales Aid (100+ pages!)
Print & Digital Advertising
Full-Page Ads for TECENTRIQ
Educational websites for consumers by Roche Products